rs1131692280
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000297.4(PKD2):c.1319+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000251 in 1,591,652 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000297.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PKD2 | NM_000297.4 | c.1319+1G>A | splice_donor_variant, intron_variant | ENST00000237596.7 | NP_000288.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PKD2 | ENST00000237596.7 | c.1319+1G>A | splice_donor_variant, intron_variant | 1 | NM_000297.4 | ENSP00000237596.2 | ||||
PKD2 | ENST00000508588.5 | c.-199+1G>A | splice_donor_variant, intron_variant | 2 | ENSP00000427131.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152196Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000798 AC: 2AN: 250634Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135442
GnomAD4 exome AF: 0.00000139 AC: 2AN: 1439456Hom.: 0 Cov.: 27 AF XY: 0.00000279 AC XY: 2AN XY: 717472
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152196Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74350
ClinVar
Submissions by phenotype
Polycystic kidney disease 2 Pathogenic:5
Pathogenic, criteria provided, single submitter | research | HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology | Aug 07, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 27, 2019 | The PKD2 c.1319+1G>A variant (rs1131692280), also known as IVS5+1G>A, is reported in the literature in multiple individuals and families affected with autosomal dominant polycystic kidney disease (ADPKD) (Magistroni 2003, Rossetti 2012, Tan 2009, Torra 2000). This variant is found on only three chromosomes (3/282036 alleles) in the Genome Aggregation Database, indicating it is not a common polymorphism, and it is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 430967). This variant abolishes the canonical splice donor site of intron 5, which is likely to disrupt gene function. Based on available information, this variant is considered to be pathogenic. References: Magistroni R et al. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003 May;14(5):1164-74. Rossetti S et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol. 2012 May;23(5):915-33. Tan YC et al. Novel method for genomic analysis of PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease. Hum Mutat. 2009 Feb;30(2):264-73. Torra R et al. Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am J Kidney Dis. 2000 Oct;36(4):728-34. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Apr 21, 2022 | PVS1 PM2 - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetics Department, Catlab | Aug 07, 2024 | The c.1319+1G>A variant in the PKD2 gene modifies the canonical donor splicing site of intron 5 and is expected to alter the protein function (PVS1). It has been previously found in multiple patients with autosomal dominant policystic kidney disease (PMID: 12707387, 11007674, 18837007) (PS4_Moderate) and it has been shown to segregate in one of our affected families (PP1). The variant has a very low frequency in the gnomAD database 4.1 (AF= 2.5e-06) (PM2). Additionally, the variant is classified as pathogenic in the ADPKD database. With all the available evidence, the variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 04, 2024 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 30, 2020 | This variant is expected to severely impact normal RNA splicing, and consequently, protein structure and/or function. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant has been identified in at least one individual with clinical features associated with this gene. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 11, 2024 | Canonical splice site variant expected to result in aberrant splicing, although in the absence of functional evidence the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 25525159, 29790872, 12707387, 18837007, 22383692, 35314260, 27499327, 36938073, 11007674) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 11, 2023 | The c.1319+1G>A intronic variant results from a G to A substitution one nucleotide(s) after coding exon 5 of the PKD2 gene. Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNAdecay; however, direct evidence is unavailable. The exact functional effect of the altered amino acid sequence is unknown; however, and a significant portion of the protein is affected (Ambry internal data). Based on data from gnomAD, the A allele has an overall frequency of 0.001% (3/282036) total alleles studied. The highest observed frequency was 0.012% (3/24960) of African alleles. This mutation has been reported in multiple individuals with a clinical diagnosis of polycystic kidney disease (Torra, 2000; Rossetti, 2012). In one individual with polycystic kidney disease, this mutation was identified in conjunction with a missense variant in PKD1 (Magistroni, 2003). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, this alteration is classified as pathogenic. - |
Polycystic kidney disease Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The PKD2 c.1319+1G>A variant was identified in 9 of 1178 proband chromosomes (frequency: 0.008) from individuals or families with ADPKD (Hwang 2016, Magistroni 2003, Rossetti 2012, Tan 2008, Torra 2000). The variant was also identified in dbSNP (ID: rs1131692280) with “Pathogenic allele”, in ClinVar (classified pathogenic by Invitae, Ambry Genetics and Hudson Alpha Institute for Biotechnology), LOVD 3.0 (2x), and the ADPKD Mutation Database (classified as definitely pathogenic). The variant was not identified in the PKD1-LOVD database. The variant was identified in 3 of 276406 chromosomes at a frequency of 0.00001 (Genome Aggregation Database Feb 27, 2017), observed in the following populations: African in 3 of 24026 chromosomes (freq: 0.0001); it was not observed in the Other, Latino, European Non-Finnish, Ashkenazi Jewish, East Asian, Finnish, and South Asian populations. The c.1319+1G>A variant is predicted to cause abnormal splicing because the nucleotide substitution occurs in the invariant region of the splice consensus sequence. In addition, 3 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. - |
Autosomal dominant polycystic kidney disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 20, 2019 | For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PKD2 are known to be pathogenic (PMID: 17582161, 22863349). Disruption of this splice site has been reported in families affected with polycystic kidney disease (PMID: 11007674, 12707387, 22383692). It is also known as IVS5+1G>A in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 5 of the PKD2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at